◐ Shell
reader mode source ↗
Jump to content
From Wikipedia, the free encyclopedia

Pharmaceutical compound
1Bz-LSD
Clinical data
Other names1-Benzoyl-LSD; SYN-L-018
Routes of
administration		Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Chemical and physical data
FormulaC27H28N3O2
Molar mass426.540 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C]1CN(C)[C@@H]2Cc3cn(C(=O)c4ccccc4)c5cccc(C2=C1)c35
  • InChI=1S/C27H28N3O2/c1-4-29(5-2)26(31)20-14-22-21-12-9-13-23-25(21)19(15-24(22)28(3)16-20)17-30(23)27(32)18-10-7-6-8-11-18/h6-14,17,24H,4-5,15-16H2,1-3H3/t24-/m1/s1
  • Key:GVGINGNTVRBWSQ-XMMPIXPASA-N

1Bz-LSD, also known as 1-benzoyl-LSD or as SYN-L-018, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is thought to be a prodrug of LSD.[1][2] The drug was patented by Lizard Labs in 2024.[2] Subsequently, it was encountered online as a novel designer drug in July 2024.[1] 1Bz-LSD has been sold in the form of blotter tabs and microdots containing 10 μg and 200 μg doses per unit.[1] 1Bz-LSD is not an explicitly controlled substance in the United States[3] or in Canada.[4]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 "1Bz-LSD". AIPSIN (in Russian). Retrieved 1 January 2026.
  2. 1 2 3 WO 2024/028495, Stratford A, Williamson JP, "Prodrugs of Substituted Ergolines", published 8 February 2024, assigned to Synex Holdings BV 
  3. ↑ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
  4. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. 5 December 2025. Retrieved 20 January 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=1Bz-LSD&oldid=1356815972"